EUVIMEDDescoperă EUVIMED
Crossref

Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

Amelie Jaeger iD, Sudheer Madan Mohan Gambheer, Xiaoyang Sun, Dmitry Chernyakov, Oleksandra Skorobohatko, Thomas Mack, Sandra Kissel, Dietmar Pfeifer, Robert Zeiser, Paul Fisch, Geoffroy Andrieux iD, Daniela Bräuer-Hartmann iD and 12 more

Blood · 2023

DOI: 10.1182/blood.2022015653 ↗

At a glance

Journal article in Blood, 2023. Written by Amelie Jaeger and 23 co-authors. Institution: Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany. Major MEDLINE topics: Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell. Cited 7 times so far (Crossref).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Peripheral T-cell lymphomas (PTCL) - especially angioimmunoblastic (AITL) and follicular TCL - have a dismal prognosis due to lack of efficient therapies, and patients` symptoms are often dominated by an inflammatory phenotype including fever, night sweats, weight loss and skin rash. In this study, we investigated the role of inflammatory granulocytes and activated cytokine signaling on PTCL-TFH (T-follicular helper type) disease progression and symptoms. We show, that ITK-SYK driven murine PTCLs and primary human PTCL-TFH xenografts both induce inflammation in mice including murine neutrophil expansion and massive cytokine release. Granulocyte/lymphoma interactions were mediated by positive autoregulatory cytokine loops involving INF-γ (CD4+malignant T-cells) and IL-6 (activated granulocytes), ultimately inducing broad JAK kinase activation (Jak1/2/3, Tyk2) in both cell types. Depletion of inflammatory granulocytes via antibodies (Ly6G), genetic granulocyte depletion (LyzM-Cre/MCL1flox/flox) or the deletion of IL-6 within microenvironmental cells blocked inflammatory symptoms, reduced lymphoma infiltration and enhanced mouse survival. Furthermore, unselective JAK kinase inhibitors (ruxolitinib) inhibited both, TCL progression and granulocyte activation in various PTCL mouse models. Our results support the important role of granulocyte-driven inflammation, cytokine-induced granulocyte/CD4+ TCL interactions and the requirement of an intact JAK/STAT signaling pathway for PTCL-TFH development, and support broad JAK kinase inhibition as an effective treatment strategy in early disease stages.

Subjects

MeSH terms (MEDLINE)

Lymphoma, T-Cell, PeripheralLymphoma, T-CellHumansAnimalsMiceInterleukin-6GranulocytesInflammation

Substances

Interleukin-6

Authors and institutions

  • Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany.
  • Hematology/Oncology and Stemcell transplantation, University of Halle-Wittenberg, Halle, Germany.
  • Department of Pathology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany.
  • Institute of Medical Bioinformatics and Systems Medicine, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany.
  • Institute of pathology, University Hospital Halle, Halle, Germany.
  • Krukenberg Cancer Center Halle, University Hospital Halle, Halle, Germany.

ORCID profiles: Amelie Jaeger, Geoffroy Andrieux, Daniela Bräuer-Hartmann, Marie Follo, Melanie Boerries, Nikolas von Bubnoff, Cornelius Miething, Thomas Weber

Cite

APA

Jaeger, A., Gambheer, S. M. M., Sun, X., Chernyakov, D., Skorobohatko, O., Mack, T., Kissel, S., Pfeifer, D., Zeiser, R., Fisch, P., Andrieux, G., Bräuer-Hartmann, D., Bauer, M., Schulze, S., Follo, M., Boerries, M., von Bubnoff, N., Miething, C., Hidalgo, J. V., …, & Dierks, C. (2023). Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. https://doi.org/10.1182/blood.2022015653

Vancouver

Jaeger A, Gambheer SMM, Sun X, Chernyakov D, Skorobohatko O, Mack T, et al. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. 2023. doi:10.1182/blood.2022015653

BibTeX
@article{Jaeger2023,
  author = {Jaeger, Amelie and Gambheer, Sudheer Madan Mohan and Sun, Xiaoyang and Chernyakov, Dmitry and Skorobohatko, Oleksandra and Mack, Thomas and Kissel, Sandra and Pfeifer, Dietmar and Zeiser, Robert and Fisch, Paul and Andrieux, Geoffroy and Bräuer-Hartmann, Daniela and Bauer, Marcus and Schulze, Susann and Follo, Marie and Boerries, Melanie and von Bubnoff, Nikolas and Miething, Cornelius and Hidalgo, Jose Villacorta and Klein, Claudius and Weber, Thomas and Wickenhauser, Claudia and Binder, Mascha and Dierks, Christine},
  title = {Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022015653}
}
Start for free →